Tumor BRCA testing can reveal a high tumor mutational burden related to POLE pathogenic variants

Tumor BRCA testing can reveal a high tumor mutational burden related to POLE pathogenic variants

Objective: Tumors harboring a POLE pathogenic variant, associated with high tumor mutational burden, are good candidates for immunotherapy. However, POLE pathogenic variants are not currently screened in routine clinical practice. Can these tumors be identified by means of an already available test?...

Full description

Bibliographic Details
Main Authors: M.-C. Villy, J. Masliah-Planchon, S. Melaabi, O. Trabelsi Grati, E. Girard, G. Bataillon, A. Vincent-Salomon, J. Le Gall, L. Golmard, D. Stoppa-Lyonnet, I. Bieche, C. Colas
Format: Article
Language:English
Published: Elsevier 2021-08-01
Series:Gynecologic Oncology Reports
Subjects:
Oncogenetics
POLE
Tumor BRCA testing
Online Access:http://www.sciencedirect.com/science/article/pii/S2352578921001594

Similar Items

Similar Items